ENOVIS

ENOVIS

Develops orthopedic and reconstructive medical devices

About ENOVIS

Simplify's Rating
Why ENOVIS is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

N/A

Headquarters

Wilmington, Delaware

Founded

2022

Overview

Enovis develops medical technology solutions aimed at improving patient outcomes and restoring mobility. The company operates in two main segments: Prevention & Recovery, which includes orthopedic solutions like bracing products and therapy systems for rehabilitation and sports medicine, and Reconstructive, which focuses on implant products for various joints and minimally invasive surgical tools. Enovis's products, including well-known brands like DonJoy and Aircast, are designed to address specific medical needs such as pain management and bone growth stimulation. What sets Enovis apart from competitors is its commitment to continuous improvement through the Enovis Growth Excellence (EGX) system, which enhances operations and customer satisfaction. The company's goal is to innovate in the medical technology field to create better outcomes for patients and healthcare providers globally.

📈
Significant Headcount Growth
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for minimally invasive surgical solutions boosts Enovis's market potential.
  • Integration of digital health technologies opens new avenues for product innovation.
  • LimaCorporate acquisition expands Enovis's market share in the European orthopedic sector.

What critics are saying

  • Increased competition from Stryker and Zimmer Biomet in the orthopedic market.
  • Potential supply chain complexities from integrating LimaCorporate operations.
  • Regulatory challenges in obtaining FDA approvals for new products.

What makes ENOVIS unique

  • Enovis offers a diverse portfolio of orthopedic and reconstructive solutions.
  • The company integrates advanced materials like vitamin E-doped polyethylene in implants.
  • Enovis's acquisition of LimaCorporate enhances its transatlantic business capabilities.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$0

Below

Industry Average

Funded Over

3 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Legal Services

Growth & Insights and Company News

Headcount

6 month growth

↑ 27%

1 year growth

↑ 30%

2 year growth

↑ 30%
MassDevice
Jan 17th, 2025
Enovis appoints new president of International Surgical business

Enovis (NYSE: ENOV) announced today that it appointed Davide Visentin as the new president of its International Surgical business.

The Manila Times
Jan 6th, 2025
Enovis to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Enovis to participate in the 43rd Annual J.P. Morgan Healthcare Conference.

MarketBeat
Jan 3rd, 2025
Confluence Investment Management LLC Makes New $3.49 Million Investment in Enovis Co. (NYSE:ENOV)

Confluence Investment Management LLC makes new $3.49 million investment in Enovis Co. (NYSE:ENOV).

MarketBeat
Nov 27th, 2024
Dynamic Technology Lab Private Ltd Makes New $1.05 Million Investment in Enovis Co. (NYSE:ENOV)

Dynamic Technology Lab Private Ltd makes new $1.05 million investment in Enovis Co. (NYSE:ENOV).

ADCBUS
Sep 10th, 2024
How Should Investors React To Colfax Corporation's (NYSE:CFX) CEO Pay?

Matt Trerotola became the CEO of Colfax Corporation (

Recently Posted Jobs

Sign up to get curated job recommendations

ENOVIS is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update ENOVIS's jobs every 8 hours, so check again soon! Browse all jobs →